FOURKITES
16.12.2021 11:43:07 CET | Business Wire | Press release
FourKites® , the world’s leading real-time supply chain visibility platform , today announced a year of record growth as the company executed on its vision to optimise global supply chains with real-time visibility data and machine learning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005527/en/
In 2021, the company saw triple-digit growth in total shipments; drove 50% growth in new customers across all industries – including Barilla Group, Beyond Meat, Cardinal Health, Haworth, LyondellBasell, McCain Foods, Roehm, Rove Concepts and Yamaha Motors. It also significantly expanded its carrier network and extended real-time visibility to more than 2,800 ports and 2.5 million facilities worldwide.
Key to its growth in 2021 was FourKites’ significant expansion in Europe. The company grew its European carrier network across carriers of all sizes, and added tangible business value with new offerings that enabled European carriers, forwarders and shippers to connect and collaborate on the world’s most trusted supply chain visibility platform. Specifically, in 2021 FourKites saw:
- 148% growth in European shipment volume, having tracked over 112 billion miles and computed over 5 billion estimated times of arrival globally
- 2X increase in new European customers
- 35% growth of its carrier network, and 110% growth of the number of European carriers on FourKites’ Premier Carrier List
- 50% growth in the number of EMEA ports and 118% growth in the number of facilities tracked per month
- The appointment of industry veterans Marc Boileau as Senior Vice President, Sales and Carrier Operations, EMEA, and Oleskii Kosenko as Director Carrier Network Operations, EMEA to accelerate regional growth momentum among both shippers and carriers
Alleviating disruptions with innovative solutions for every mode
Amid another year of constant disruptions, FourKites doubled-down on its customer-driven innovation model, with more than 65 new features resulting from customer feedback. These industry-first capabilities help FourKites users track shipments end-to-end across all modes and geographies, from sourcing to manufacturing to final destination.
These innovations included the patented Smart Forecasted Arrival (SFA) that provides frequent and highly accurate ETAs even for untrackable freight in transit; Dynamic ETA® for Ocean ; Dynamic ETA® for Air ; a major upgrade to Dynamic YardSM ; its new Order Intelligence Hub (OIH), which provides a single-pane-of-glass view of the entire lifecycle of every order; and powerful new collaboration features – including Instant Messaging, an updated CarrierLink mobile app for drivers, and enhancements to Partner Hub , its self-service, secure GPS onboarding solution for brokers and carriers.
Forging powerful new partnerships to accelerate end-to-end visibility
In 2021, FourKites forged new strategic partnerships with global supply chain and technology leaders as it continues to execute on its bold vision for the future of digital supply chains, where automated, interconnected and collaborative supply chains are optimised by real-time visibility data and machine learning.
New partnerships in 2021 include a global partnership with Zebra Technologies Corporation (NASDAQ: ZBRA), in which Zebra is now reselling FourKites’ Dynamic Yard and real-time visibility platform as part of its suite of asset visibility solutions. Additionally, Zebra’s MotionWorks Yard solution has been integrated with FourKites Dynamic Yard and Zebra locationing hardware and professional services to increase the in-yard and over-the-road capabilities of their customers.
“We have seen tremendous growth in Europe over the past year, and we look forward to another year of record-breaking momentum," said FourKites founder and CEO Mathew Elenjickal. "Behind each success and innovation are tenacious and passionate employees, customers, and partners who keep redefining what’s possible. I'm grateful to be part of such an awe-inspiring community.”
FourKites’ market leadership was recognised via several prestigious industry reports, including being named a leader in the 2021 Gartner Magic Quadrant for Real-Time Transportation Visibility Platforms .
Customers and carriers in their own words
“The collaboration that we've talked about in logistics for 20 years is now real. And the better that you can collaborate and integrate with your carriers, the more effective you'll be in delivering to your customer’s expectations, which is in the end, what it's all about. FourKites is more than just track-and-trace, it's about the visibility and how we're going to use it to start to drive efficiencies.”
Paul Avampato, Head of International Logistics, Henkel
“Working with AB InBev’s FourKites platform allows us to offer a better service. FourKites makes it so easy for us to feed GPS data into AB InBev’s platform. And now, thanks to being on FourKites’ Premier Carrier List, we’re confident we’ll get even more business from customers who want excellent visibility into their supply chains.”
Roy van der Heijden, business analyst at Int. transportbedrijf van der Heijden b.v.
“Every day, our carriers automatically share location data with our FourKites platform on hundreds of loads throughout Europe. We are able to track our products minute by minute and, in real time, pass on detailed arrival times to our customers. This means the distributors we supply always know their stock situation and end customers can depend on us to get them the seeds and crop protection they need, when they need them.”
Edmund Jager, Head of Distribution EMEA at Bayer
About FourKites
FourKites® is the #1 supply chain visibility platform in the world, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching 176 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 750 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005527/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
